Melissa Burns

Clinical trials

• Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

  Principal investigator · Active not recruiting · Phase 3

  Dana-Farber Cancer Institute

  2017–2034
• Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2025–2028
• A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2025–2030
• Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  Site PI · Recruiting · Phase 3

  Children's Oncology Group

  2019–2032